The underwriters took up the option to buy another 2.7 million shares after the Pfizer and Gilead-backed oncology therapy developer's shares leapt substantially post-IPO.
US-based immuno-oncology drug developer Allogene Therapeutics closed an initial public offering that scored exits for pharmaceutical companies Pfizer and Gilead Sciences at almost $373m yesterday.
The company raised an initial $324m last week when it issued 18 million shares priced at the top of their range at $18.00 each on the Nasdaq Global Select Market.
Allogene’s shares closed at $25.00 on their first day of trading on Thursday, and at $26.96 yesterday. Joint book-running managers Goldman Sachs, JP Morgan…
